Expression of glucose transporters in cancers

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 164-169

  Szablewski, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cancers; GLUTs expression; SGLTs expression

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 12; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 5; SMALL INTERFERING RNA; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 3; SODIUM GLUCOSE COTRANSPORTER 5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BREAST CANCER; BREAST PAPILLOMA; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG TARGETING; GENE OVEREXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MOLECULAR IMAGING; NEURILEMOMA; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW;

ANIMALS; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84872478184     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.12.004     Document Type: Review

References (94)

1. Szablewski L. Glucose Homeostasis and Insulin Resistance 2011, Bentham eBook. first ed.
2. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
3. Horsman M.R. Measurement of tumor oxygenation. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42:701-704.
4. Isa A.Y., Ward T.H., West C.M.L., Slevin N.J., Homer J.J. Hypoxia in head and neck cancer. Br. J. Radiol. 2006, 79:791-798.
5. Airley R., Loncaster J., Davidson S., Bromley M., Roberts S., Patterson A., Hunter R., Stratford I., West C. Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis - free survival in advanced carcinoma of the cervix. Cancer Res. 2001, 7:928-934.
6. Gatenby R.A., Smallbone K., Maini P.K., Rose F., Averill J., Nagle R.B., Worrall L., Gillies R.J. Cellular adaptation to hypoxia and acidosis during somatic evolution of breast cancer. Br. J. Cancer 2007, 97:646-653.
7. Schwartz M.K. Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin. Chim. Acta 1992, 206:77-82.
8. Board M., Humm S., Newsholme E.A. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells. Biochem. J. 1990, 265:503-509.
9. Mc Dermott E.W., Barron E.T., Smyth P.P., O'Higgins N.J. Premorphological metabolic changes in human breast carcinogenesis. Br. J. Surg. 1990, 77:1179-1182.
10. Wright E.M., Turk E. The sodium/glucose cotransport family SLC5. Pflügers Arch. 2004, 447:510-518.
11. Wright E.M., Loo D.D.F., Hirayama B.A. Biology of human sodium glucose transporters. Physiol. Rev. 2011, 91:733-794.
12. Diez-Sampedro A., Hirayama B.A., Osswald C., Gorboulev V., Baumgarten K., Volk C., Wright E.M., Koepsell H. A glucose sensor hinding in a family of transporters. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11753-11758.
13. Nishimura M., Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet. 2005, 20:452-477.
14. Casneuf V.F., Fonteyne P., Van Damme N., Demetter P., Pauwels P., de Hemptinne B., Vos M., Van de Wiele C., Petters M. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest. 2008, 26:852-859.
15. Helmke B.M., Reisser C., Idzko M., Dyckhoff G., Herold-Mende C. Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. Oral Oncol. 2004, 40:28-35.
16. Ishikawa N., Oguri T., Isobe T., Fujitaka K., Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn. J. Cancer Res. 2001, 92:874-879.
17. Weihua Z., Tsan R., Huang W.-C., Wu Q., Chiu C.-H., Fidler I.J., Hung M.-C. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
18. Engelman J.A., Cantley L.C. A sweet new role for EGFR in cancer. Cancer Cell 2008, 13:375-376.
19. Calvo M.B., Figureoa A., Pulido E.G., Campelo R.G., Aparicio L.A. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int. J. Endocrinol. 2010, 10.1155/2010/205357.
20. LeFevre P.G. Evidence of active transfer of certain non-electrolytes across the human red cell membrane. J. Gen. Physiol. 1948, 31:505-527.
21. Pao S.S., Paulsen I.T., Saier M.H. Major facilitator superfamily. Microbiol. Mol. Biol. Rev. (Washington, DC) 1998, 62:1-34.
22. Thorens B., Mueckler M. Glucose transporters in the 21st century. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E141-E145.
23. Joost H.G., Bell G.L., Best J.D., Birnbaum M.J., Charron M.J., Chen Y.T., Doege H., James D.E., Lodish H.F., Moley K.H., Moley J.F., Mueckler M., Rogers S., Schurmann A., Seino S., Thorens B. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E974-E976.
24. Ganapathy V., Thangarju M., Prasad P.D. Nutrients transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Therapeut. 2009, 121:29-40.
25. Medina R.A., Owen G.I. Glucose transporters: expression, regulation and cancer. Biol. Res. 2002, 35. 10.4067/S0716-97602002000100004.
26. Yamamoto T., Seino Y., Fukumoto H., Koh G., Yano H., Inagaki N., Yamada Y., Inoue K., Manabe T., Imura H. Over-expression of the facilitative glucose transporter genes in human cancer. Biochem. Biophys. Res. Commun. 1990, 170:223-230.
27. Brown R.S., Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. Cancer 1993, 72:2979-2985.
28. Cantuaria G., Magalhaes A., Penalver M., Angioli R., Braunschweiger P., Gomez-Marin O., Kanhoush R., Gomez-Fernandez C., Nadji M. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol. Oncol. 2000, 79:33-37.
29. Carvalho K.C., Cunha I.W., Rocha R.M., Ayala F.A., Cajaíba M.M., Begnami M.D., Vilela R.S., Paiva G.R., Andrade R.G., Soares F.A. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics 2011, 66:965-972.
30. Burstein D.E., Reder I., Weiser K., Tong T., Pritsker A., Haber R.S. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions. Mod. Pathol. 1998, 11:392-396.
31. Brown R.S., Goodman T.M., Zasadny K.R., Greenson J.K., Wahl R.L. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl. Med. Biol. 2002, 29:443-453.
32. Chandler J.D., Williams E.D., Slavin J.L., Best J.D., Rogers S. Expression and localization of GLUT 1 and GLUT 12 in prostate carcinoma. Cancer 2003, 97:2035-2042.
33. Jans J., van Dijk J.H., van Schelven S., van der Groep P., Willems S.H., Jonges T.N., Diest P.J., Bosch J.L. Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy. Urology 2010, 75:786-792.
34. Endo M., Tateishi U., Seki K., Yamaguchi U., Nakatani F., Kawai A., Chuman H., Beppu Y. Prognostic implications of glucose transporter protein-1 (Glut-1) overexpression in bone and soft-tissue sarcomas. Jpn. J. Clin. Oncol. 2007, 37:955-960.
35. Cantuaria G., Fagotti A., Ferrendina G., Magalhaes A., Nadji M., Angioli R., Penalver M., Manusco S., Scambia G. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001, 92:1144-1150.
36. Semaan A., Munkarah A.R., Arabi H., Bandyopadhyay S., Seward S., Kumar S., Qazi A., Hussein Y., Morris R.T., Ali-Fehmi R. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol. Oncol. 2011, 121:181-186.
37. Haber R.S., Rathan A., Weiser K.R., Prtsker A., Itzkowitz S.H., Bodian C., Slater G., Weiss A., Burstein D.E. Glut 1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998, 83:34-40.
38. Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997, 80:1046-1051.
39. Younes M., Brown R.W., Mody D.R., Fernandez L., Lauricia R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer. Res. 1995, 15:2895-2898.
40. Ayala F.R.R., Rocha R.M., Carvalho K.C., Carvalho A.L., Werneck da Cunha I., Lourenço S.V., Soares F.A. Glut 1 and Glut 3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 2010, 15:2374-2387.
41. Oliver R.J., Woodwards R.T.M., Sloan P., Thakker N.S., Stratford I.I., Airley R.E. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: results of EORTC translational research fund studies. Eur. J. Cancer 2004, 40:503-507.
42. Chiba I., Ogawa K., Morioka T., Shimoji H., Sunagawa N., Iraha S., Nishimaki T., Yoshimi N., Murayama S. Clinical significance of GLUT-1 expression in patients with esophageal cancer treated with concurrent chemioradiotherapy. Oncol. Lett. 2011, 2:211-228.
43. Cooper R., Sariolu S., Sökmen S., Füzün M., Küpeliolu A., Valentine H., Görken I.B., Airley R., West C. Glucose transporter-1 (GLUT-1): a potential marker of prognostic in rectal carcinoma. Br. J. Cancer 2003, 89:870-876.
44. Choi Y.S., Kim S.J., Kim D.S., Park S.J., Park Y., Shin H.J., Jung K.-Y., Baek S.-K., Shin B.K., Choi J.W., Kim B.S., Shin S.W., Kim Y.H., Kim J.S. Glucose transporter-1 expression in squamous cell carcinoma of the tongue. Cancer Res. Treat. 2007, 39:109-115.
45. Parente P., Coli A., Massi G., Mangoni A., Fabrizi M.A., Bigotti G. Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J. Exp. Clin. Cancer Res. 2008, 27:34.
46. Lee J.-H., Kim Y.-W., Cheng S.-G. Glucose transporter-1 expression in urothelial papilloma of the bladder. Urol. Int. 2005, 74:268-271.
47. Noguchi Y., Marat D., Saito A., Yoshikawa T., Doi C., Fukuzawa K., Tsuburaya A., Satoh S., Ito T. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology 1999, 46:2683-2689.
48. Godoy A., Ulloa V., Rodríguez F., Reinicke K., Yañez A.I., Garcia Mde L., Medina R.A., Carrasco M., Barberis S., Castro T., Martínez F., Koch X., Vera J.C., Poblete M.T., Figueroa C.D., Peruzzo B., Pérez F., Nualart F. Differential subcellular distribution of glucose transporters GLUT 1-6 and GLUT 9 in human cancer: ultrastructural localization of GLUT 1 and GLUT 5 in breast tumor tissues. J. Cell. Physiol. 2006, 207:614-627.
49. Seino Y., Yamamoto T., Inoue K., Imamura M., Kadowaki S., Kojima H., Fujikawa J., Imura H. Abnormal facilitative glucose transporter gene expression in human islet cell tumors. J. Clin. Endocrinol. Metab. 1993, 76:75-78.
50. Fendrich V., Schneider R., Maitra A., Jacobsen I.D., Opferman T., Bartsch D.K. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia 2011, 13:180-186.
51. Boado R.J., Black K.L., Pardgride W.M. Expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res. Mol. Brain Res. 1994, 27:51-57.
52. Binder C., Binder I., Marx D., Schauer A., Hiddemann W. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer. Res. 1997, 17:4299-4304.
53. Younes M., Lechago L.V., Somoano J.R., Mosharaf M., Lechago J. Immunohistochemical detection of GLUT3 in human tumors and normal tissues. Anticancer. Res. 1997, 17:2747-2750.
54. Mellanen P., Minn H., Grenman R., Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int. J. Cancer 1994, 56:622-629.
55. Reisser C., Eichhorn K., Herold-Mende C., Born A.I., Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int. J. Cancer 1999, 80:194-198.
56. Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod. Pathol. 1998, 11:437-443.
57. Kurata T., Oguri T., Isobe T., Ishioka S., Yamakido M. Differential expression of facilitative glucose transporter (GLUT) genes in primary lung cancers and their liver metastases. Jpn. J. Cancer Res. 1999, 90:1238-1243.
58. Glick R.P., Unterman T.G., Lacson R. Identification of insulin-like growth factor (IGF) and glucose transporter-1 and -3 mRNA in CNS tumors. Regul. Pept. 1993, 48:251-256.
59. Hirose Y., Kaida H., Ishibashi M., Kawahara A., Kobayashi M., Hayabuchi N. Glucose transporter expression of intraductal papilloma of the breast detected by fluorodeoxyglucose positron emission tomography. Jpn. J. Radiol. 2011, 29:217-221.
60. Reske S.N., Grillenberger K.G., Glatting G., Port M., Hildebrandt M., Gansauge F. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J. Nucl. Med. 1997, 38:1344-1348.
61. Liu J., Knezetic A., Strömmer L., Permert J., Larsson J., Adrian T.E. The intracellular mechanism of insulin resistance in pancreatic cancer patients. J. Clin. Endocrinol. Metab. 2000, 85:1232-1238.
62. Gowrishankar G., Zitzman-Kolbe S., Junulula A., Reeves R., Levi J., Srinivasan A., Bruus J.K., Cyr J., Dinkelborg L., Gambhir S.S. GLUT 5 is not over-expressed in breast cancer cells and patient breast cancer tissues. PLoS One 2011, 6:e26902.
63. Zamora-León S.P., Golde D.W., Concha I.I., Rivas C.I., Delgado-López F., Baselga J., Nualart F., Vera J.C. Expression of fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1847-1852.
64. Reinicke K., Sotomayor P., Cisterna P., Delgado C., Nualart F., Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J. Cell. Biochem. 2012, 113:553-562.
65. Rogers S., Macheda M.L., Docherty S.E., Carty M.D., Henderson M.A., Soeller W.C. Identification of a novel glucose transporter-like protein - GLUT12. Am. J. Physiol. Endocrinol. Metab. 2002, 283:E733-E738.
66. Rogers S., Docherty S.E., Slavin J.L., Henderson M.A., Best J.D. Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett. 2003, 193:225-233.
67. Macheda M.L., Rogers S., Bert J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2005, 202:654-662.
68. Amann T., Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin. Ther. Targets 2009, 13:1411-1427.
69. Amann T., Maegdefrau U., Hartmann A., Agaimy A., Marienhagen J., Weiss T.S., Stoeltzing O., Warneck C., Schölmerich J., Oefner P.J., Kreutz M., Bosserhoff A.K., Hellerbrand C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am. J. Pathol. 2009, 174:1544-1552.
70. Chen C.P., Li X.X., Zhang L.R., Min J.M., Chan J.Y., Fung K.O., Wang S.Q., Zhang L.H. Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG2 and MCF-7 cells. Bioconjug. Chem. 2002, 13:525-529.
71. Liu T.-Q., Fan J., Zhou L., Zheng S.-S. Effects of suppressing glucose transporter-1 by the antisense oligodeoxynucleotide on the growth of human hepatocellular carcinoma cells, Hepatobiliary Pancreat. Dis. Int. 2011, 10:72-77.
72. Chan K.K., Chan J.Y.W., Chung K.K.W., Fung K.-P. Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5. J. Cell. Biochem. 2004, 93:1134-1142.
73. Rastogi S., Banerjee S., Chellappan S., Simon G.R. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett. 2007, 257:244-251.
74. Orrock J.M., Abbott J.J., Gibson L.E., Folpe A.L. INI1 and GLUT-1 expression in epitheloid sarcoma and its cutaneous neoplastic mimics. Am. J. Dermatopathol. 2009, 31:152-156.
75. 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol. Rep. 2010, 23:1069-1076.
76. Ahrens W.A., Ridenour R.V., Caron B.L., Miller D.V., Folpe A.L. GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum. Pathol. 2008, 39:1519-1526.
77. Endo M., Tateishi U., Seki K., Yamaguchi U., Nakatani F., Kawai A., Chuman H., Beppu Y. Prognostic implications of glucose transporter protein-1 (Glut-1) overexpression in bone and soft-tissue sarcomas. Jpn. J. Clin. Oncol. 2007, 7:955-960.
78. Koga H., Matsuo Y., Sasaki M., Nakagawa M., Kaneko K., Hayashi K., Kubawara Y., Honda H. Differential FDG accumulation associated with GLUT-1 expression in patients with lymphoma. Ann. Nucl. Med. 2003, 17:327-331.
79. Airley R.E., Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53:233-256.
80. Shima H.K., Lee W.W., Park S.Y., Kim H., So Y., Kim S.E. Expression of glucose transporter types 1 and 3 and hexokinase II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas. Nucl. Med. Biol. 2009, 36:191-197.
81. Minamimoto R., Senda M., Terauchi T., Jinnouchi S., Inoue T., Iinuma T., Inoue T., Ito K., Iwata H., Uno S., Oguchi K., Tsukamoto E., Nakashima R., Nishizawa S., Fukuda H., Murano T., Yoshida T. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey. Ann. Nucl. Med. 2011, 25:45-54.
82. Storto G., Di Giorgio E., De Renzo A., Pizzuti L.M., Cerciello G., Nardelli A., Capacchione D., Castaldi E., Ortosecco G., Pace L. Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma. Br. J. Haematol. 2010, 151:195-197.
83. Chandler J.D., Williams E.D., Slavin J.L., Best J.D., Rogers S. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer 2003, 97:2035-2042.
84. 18F-FDG PET and PET/CT in fever of unknown origin. J. Nucl. Med. 2007, 48:35-45.
85. 18F] FDG uptake and PCNA, Glut1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005, 7:369-379.
86. Kaira K., Oriuchi N., Sunaga N., Ishizuka T., Shimizu K., Yamamoto N. A systemic review of PET and biology in lung cancer. Am. J. Transl. 2011, 3:383-391.
87. 18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J. Clin. Oncol. 2010, 28:3746-3753.
88. 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig. Dis. Sci. 2006, 51:2198-2205.
89. Fendrich V., Schneider R., Maitra A., Jacobsen I.D., Opfermann T., Bartsch D.K. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Neoplasia 2011, 13:180-186.
90. Abrantes A.M., Martins M., Gonçalves A.C., Rodrigues M.C., Mamede A.C., Tavares S.D., Lima J.M., Rodrigues A., Sarmento-Ribeiro A.B., Botelho M.F. GLUT expression and 18-F-FDG uptake in breast cancer cell lines. BMC Proc. 2010, 4(Suppl. 2):21.
91. Yamada K., Brink I., Bissé E., Epting T., Engelhardt R. Factors influencing [F-18]-2-fluoro-2-deoxy-D-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J. Dermatol. 2005, 32:316-334.
92. 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res. 2005, 65:698-702.
93. Matsuzu K., Fernando S., Matsuzu U., Carter A., Bowden D.W., Perrier N.D. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 2004, 14:806-812.
94. Hamada K., Tomiya Y., Qiu Y., Tomoeda M., Ueda T., Tamai N., Hashimoto N., Yoshikawa H., Aozasa K., Hatazawa J. (18)F-FDG PET analysis of schwannoma: increase of SUVmax in the delayed scan is correlated with elevated VEGF/VPF expression in the tumors. Skeletal Radiol. 2009, 38:261-266.